OFI Invest Asset Management Buys 133 Shares of Becton, Dickinson and Company $BDX

OFI Invest Asset Management boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.3% in the second quarter, HoldingsChannel reports. The firm owned 5,884 shares of the medical instruments supplier’s stock after purchasing an additional 133 shares during the quarter. OFI Invest Asset Management’s holdings in Becton, Dickinson and Company were worth $1,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Franklin Parlapiano Turner & Welch LLC lifted its holdings in shares of Becton, Dickinson and Company by 11.5% during the second quarter. Franklin Parlapiano Turner & Welch LLC now owns 36,160 shares of the medical instruments supplier’s stock worth $6,229,000 after buying an additional 3,737 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 20.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,493 shares of the medical instruments supplier’s stock worth $3,704,000 after buying an additional 3,637 shares in the last quarter. Concurrent Investment Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 20.3% during the second quarter. Concurrent Investment Advisors LLC now owns 13,742 shares of the medical instruments supplier’s stock worth $2,367,000 after buying an additional 2,319 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $61,000. Finally, Louisbourg Investments Inc. lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the second quarter. Louisbourg Investments Inc. now owns 49,590 shares of the medical instruments supplier’s stock worth $8,542,000 after buying an additional 13,080 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BDX. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Morgan Stanley boosted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Down 1.4%

Shares of NYSE BDX opened at $186.41 on Monday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market cap of $53.43 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock has a 50-day moving average price of $190.07 and a two-hundred day moving average price of $185.73.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,023 shares of company stock valued at $562,036. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.